| DrugRepV_0008 | Alverine Citrate | Alimentary Tract and Metabolism | Spasms of the stomach and intestines | Zika virus | GZ01, a recent Asian lineage | NA | Plaque assay | Decrease (60 %) | Approved | 29033372 |
| DrugRepV_0233 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (1.35 ± 1.35 Ct) | Approved | 27801778 |
| DrugRepV_0234 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (2.21 ± 1.08 Ct) | Approved | 27801778 |
| DrugRepV_0235 | Esomeprazole Magnesium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (1.05 ± 0.79 Ct) | Approved | 27801778 |
| DrugRepV_0236 | Esomeprazole Magnesium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (1.62 ± 0.36 Ct) | Approved | 27801778 |
| DrugRepV_0254 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (0.86 ± 0.22 Ct) | Approved | 27801778 |
| DrugRepV_0255 | Esomeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (0.78 ± 0.25 Ct) | Approved | 27801778 |
| DrugRepV_0372 | Chlorhexidine Diacetate | Alimentary Tract and Metabolism | Disinfectant, oropharyngeal decontamination | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0380 | Dicyclomine Hydrochloride | Alimentary Tract and Metabolism | Bowel/irritable bowel syndrome | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0391 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0566 | Alverine Citrate | Alimentary Tract and Metabolism | Muscle spasms | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0612 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (83 %) | Approved | 23577127 |
| DrugRepV_0622 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (28 %) | Approved | 23577127 |
| DrugRepV_0641 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Lassa virus | Josiah | NA | Real-time PCR | No significant effect | Approved | 23577127 |
| DrugRepV_0651 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (95 %) | Approved | 23577127 |
| DrugRepV_0661 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (89 %) | Approved | 23577127 |
| DrugRepV_0675 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved | 23577127 |
| DrugRepV_0685 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (95 %) | Approved | 23577127 |
| DrugRepV_0697 | Diphenoxylate | Alimentary Tract and Metabolism | Diarrhea | Ebola virus | EBOLA-eGFP | NA | Fluorescence-based assay | Decrease | Approved | 23577127 |
| DrugRepV_0706 | Oxyphencyclimine | Alimentary Tract and Metabolism | Peptic ulcers | Ebola virus | EBOLA-eGFP | NA | Fluorescence-based assay | No significant effect | Approved | 23577127 |
| DrugRepV_0775 | Chlorhexidine Dihydrochloride | Alimentary Tract and Metabolism | Disinfectant, oropharyngeal decontamination | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (97.965 %) | Approved | 27476412 |
| DrugRepV_0783 | Palonosetron Hydrochloride | Alimentary Tract and Metabolism | Nausea and vomiting associated with cancer chemotherapy | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (87.615 %) | Approved, Investigational | 27476412 |
| DrugRepV_0824 | Rabeprazole Sodium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) | Peptic ulcer disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.765 %) | Approved, Investigational | 27476412 |
| DrugRepV_0829 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (60.145 %) | Approved | 27476412 |
| DrugRepV_0858 | Calcitriol | Alimentary Tract and Metabolism | Vitamin D resistant rickets | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.57 %) | Approved | 27476412 |
| DrugRepV_0862 | Chenodiol | Alimentary Tract and Metabolism | Radiolucent stones | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.095 %) | Approved | 27476412 |
| DrugRepV_0881 | Metoclopramide Hydrochloride | Alimentary Tract and Metabolism | Gastroesophageal reflux disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (59.405 %) | Approved, Investigational | 27476412 |
| DrugRepV_0882 | Mepenzolate Bromide | Alimentary Tract and Metabolism | Peptic ulcer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.065 %) | Approved | 27476412 |
| DrugRepV_0898 | Acarbose | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.59 %) | Approved | 27476412 |
| DrugRepV_0911 | L-Ascorbic Acid | Alimentary Tract and Metabolism | Vitamin C deficiency | Scurvy | Delayed wound and bone healing | Urine acidification | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.58 %) | Approved, Nutraceutical | 27476412 |
| DrugRepV_0915 | Loperamide Hydrochloride | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.78 %) | Approved | 27476412 |
| DrugRepV_0927 | Famotidine | Alimentary Tract and Metabolism | Peptic ulcer | Gastroesophageal reflux disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.495 %) | Approved | 27476412 |
| DrugRepV_0934 | Pantoprazole | Alimentary Tract and Metabolism | Gastroesophageal reflux disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.82 %) | Approved | 27476412 |
| DrugRepV_0941 | Alosetron Hydrochloride | Alimentary Tract and Metabolism | Diarrhea | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.005 %) | Approved | 27476412 |
| DrugRepV_0944 | Acetohexamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.13 %) | Approved, Withdrawn | 27476412 |
| DrugRepV_0947 | Rosiglitazone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.78 %) | Approved | 27476412 |
| DrugRepV_0954 | Nitisinone | Alimentary Tract and Metabolism | Hereditary tyrosinemia type 1 | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.205 %) | Approved | 27476412 |
| DrugRepV_0961 | Pioglitazone Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.685 %) | Approved, Investigational | 27476412 |
| DrugRepV_0967 | Chlorpropamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.46 %) | Approved | 27476412 |
| DrugRepV_0991 | Sodium Phenylbutyrate | Alimentary Tract and Metabolism | Chronic urea cycle disorder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.64 %) | Approved | 27476412 |
| DrugRepV_0995 | Trientine Dihydrochloride | Alimentary Tract and Metabolism | Wilson disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.41 %) | Approved | 27476412 |
| DrugRepV_1002 | Balsalazide | Alimentary Tract and Metabolism | Active ulcerative colitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.825 %) | Approved | 27476412 |
| DrugRepV_1017 | Ranitidine Hydrochloride | Alimentary Tract and Metabolism | Duodenal ulcer | Pathological hypersecretion of gastric acid | Gastric ulcer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.44 %) | Approved, Withdrawn | 27476412 |
| DrugRepV_1023 | Tolbutamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.45 %) | Approved, Investigational | 27476412 |
| DrugRepV_1030 | Bisacodyl | Alimentary Tract and Metabolism | Colon cleansing | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.3 %) | Approved | 27476412 |
| DrugRepV_1064 | Glipizide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.385 %) | Approved, Investigational | 27476412 |
| DrugRepV_1065 | Nateglinide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.745 %) | Approved, Investigational | 27476412 |
| DrugRepV_1072 | Miglitol | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.84 %) | Approved | 27476412 |
| DrugRepV_1079 | Sitagliptin Phosphate | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.02 %) | Approved, Investigational | 27476412 |
| DrugRepV_1092 | Colistin Sulfate | Alimentary Tract and Metabolism | Bacterial infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.875 %) | Approved | 27476412 |
| DrugRepV_1102 | Paromomycin Sulfate | Alimentary Tract and Metabolism | Intestinal Amebiasis | Hepatic coma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.015 %) | Approved | 27476412 |
| DrugRepV_1159 | Esomeprazole Potassium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.98 %) | Approved | 27476412 |
| DrugRepV_1166 | Repaglinide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.1 %) | Approved, Investigational | 27476412 |
| DrugRepV_1169 | Orlistat | Alimentary Tract and Metabolism | Obesity | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.835 %) | Approved, Investigational | 27476412 |
| DrugRepV_1194 | Cimetidine | Alimentary Tract and Metabolism | Peptic ulcers, heartburn and acid indigestion | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.79 %) | Approved | 27476412 |
| DrugRepV_1199 | Rifaximin | Alimentary Tract and Metabolism | Traveller's Diarrhea | Irritable bowel syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.745 %) | Approved, Investigational | 27476412 |
| DrugRepV_1206 | Lansoprazole | Alimentary Tract and Metabolism | Gastric acid secretion | Gastric ulcers, active duodenal ulcers | Erosive reflux oesophagitis | Gastroesophageal reflux disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.545 %) | Approved, Investigational | 27476412 |
| DrugRepV_1223 | Metformin Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.215 %) | Approved | 27476412 |
| DrugRepV_1266 | Miglustat | Alimentary Tract and Metabolism | Gaucher's disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.98 %) | Approved | 27476412 |
| DrugRepV_1301 | Glimepiride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.29 %) | Approved | 27476412 |
| DrugRepV_1322 | Misoprostol | Alimentary Tract and Metabolism | Gastric ulcer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.33 %) | Approved | 27476412 |
| DrugRepV_1329 | Mesalamine | Alimentary Tract and Metabolism | Ulcerative colitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.935 %) | Approved | 27476412 |
| DrugRepV_1346 | Dolasetron | Alimentary Tract and Metabolism | Nausea and vomiting | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.42 %) | Approved | 27476412 |
| DrugRepV_1349 | Tolazamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.11 %) | Approved | 27476412 |
| DrugRepV_1351 | Sulfasalazine | Alimentary Tract and Metabolism | Inflammatory bowel diseases | Crohn disease | Rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.285 %) | Approved | 27476412 |
| DrugRepV_1358 | Levocarnitine | Alimentary Tract and Metabolism | Carnitine deficiency | Hyperlipoproteinemias | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.09 %) | Approved, Investigational | 27476412 |
| DrugRepV_1359 | Lactulose | Alimentary Tract and Metabolism | Constipation | Hepatic encephalopathy | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.74 %) | Approved | 27476412 |
| DrugRepV_1366 | Granisetron Hydrochloride | Alimentary Tract and Metabolism | Nausea | Vomiting | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.96 %) | Approved, Investigational | 27476412 |
| DrugRepV_1373 | Olsalazine Sodium | Alimentary Tract and Metabolism | Inflammatory Bowel Disease | Ulcerative Colitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.435 %) | Approved | 27476412 |
| DrugRepV_1376 | Betaine | Alimentary Tract and Metabolism | NA | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.565 %) | Approved, Nutraceutical | 27476412 |
| DrugRepV_1395 | Dicyclomine Hydrochloride | Alimentary Tract and Metabolism | Bowel/irritable bowel syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (39.09 %) | Approved | 27476412 |
| DrugRepV_1399 | Ondansetron | Alimentary Tract and Metabolism | Nausea | Vomiting | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.655 %) | Approved | 27476412 |
| DrugRepV_1405 | Glyburide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.39 %) | Approved | 27476412 |
| DrugRepV_1429 | Nizatidine | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) | Peptic ulcer disease | Active benign gastric ulcer | Active duodenal ulcer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.075 %) | Approved | 27476412 |
| DrugRepV_1532 | Aprepitant | Alimentary Tract and Metabolism | Nausea and vomiting | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (19.16 %) | Approved | 27476412 |
| DrugRepV_1625 | Glyburide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Influenza virus | A/Anhui/01/2013 |  | Transcriptomic response-DEG | Decrease | Approved | 24991006 |
| DrugRepV_1675 | Anethole Trithione | Alimentary Tract and Metabolism | Xerostomia and salivary gland hypofunction | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1746 | Anethole Trithione | Alimentary Tract and Metabolism | Xerostomia and salivary gland hypofunction | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1817 | Anethole Trithione | Alimentary Tract and Metabolism | Xerostomia and salivary gland hypofunction | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_2037 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2041 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2045 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2160 | Calcitriol | Alimentary Tract and Metabolism | Vitamin D deficiency | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (57.47978 %) | Approved | 27742486 |
| DrugRepV_2165 | Repaglinide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (48.7632872 %) | Approved, Investigational | 27742486 |
| DrugRepV_2174 | Aprepitant | Alimentary Tract and Metabolism | Nausea and vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (18.8613362 %) | Approved | 27742486 |
| DrugRepV_2194 | Nateglinide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.5810833 %) | Approved, Investigational | 27742486 |
| DrugRepV_2234 | Rifaximin | Alimentary Tract and Metabolism | Traveller's Diarrhea | Irritable bowel syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.80622494 %) | Approved, Investigational | 27742486 |
| DrugRepV_2270 | Trimebutine | Alimentary Tract and Metabolism | Irritable bowel syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.01937948 %) | Approved | 27742486 |
| DrugRepV_2274 | Roxatidine Acetate Hydrochloride | Alimentary Tract and Metabolism | Gastro-intestinal disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.9480885 %) | Experimental | 27742486 |
| DrugRepV_2300 | Lubiprostone | Alimentary Tract and Metabolism | Constipation | Irritable bowel syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.40977237 %) | Approved, Investigational | 27742486 |
| DrugRepV_2302 | Tropisetron | Alimentary Tract and Metabolism | Nausea and vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.39903618 %) | Approved | 27742486 |
| DrugRepV_2320 | Pioglitazone Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.84924548 %) | Approved, Investigational | 27742486 |
| DrugRepV_2330 | Rosiglitazone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.65071465 %) | Approved | 27742486 |
| DrugRepV_2332 | Metformin Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.60501062 %) | Approved | 27742486 |
| DrugRepV_2333 | Chenodiol | Alimentary Tract and Metabolism | Radiolucent Cholestrol gallstones | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.59183631 %) | Approved | 27742486 |
| DrugRepV_2336 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.4755509 %) | Approved | 27742486 |
| DrugRepV_2351 | Loperamide Hydrochloride | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.23233156 %) | Approved | 27742486 |
| DrugRepV_2386 | Gliquidone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.39646573 %) | Approved | 27742486 |
| DrugRepV_2397 | Lafutidine | Alimentary Tract and Metabolism | Peptic Ulcer | Pneumonia | Gastroesophageal Reflux Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.27113814 %) | Investigational | 27742486 |
| DrugRepV_2400 | Lansoprazole | Alimentary Tract and Metabolism | Gastric acid secretion | Gastric ulcers, active duodenal ulcers | Erosive reflux oesophagitis | Gastroesophageal reflux disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.21219908 %) | Approved, Investigational | 27742486 |
| DrugRepV_2428 | L-Glutamine | Alimentary Tract and Metabolism | Nutritional supplementation | Sickle cell disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.67790051 %) | Approved, Investigational, Nutraceutical | 27742486 |
| DrugRepV_2431 | Mitiglinide Calcium | Alimentary Tract and Metabolism | Type 2 diabetes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.63590267 %) | Investigational | 27742486 |
| DrugRepV_2442 | Granisetron Hydrochloride | Alimentary Tract and Metabolism | Nausea | Vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.32603653 %) | Approved, Investigational | 27742486 |
| DrugRepV_2453 | Rosiglitazone Maleate | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.00342918 %) | Approved, Investigational | 27742486 |
| DrugRepV_2454 | Ondansetron Hydrochloride | Alimentary Tract and Metabolism | Nausea | Vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.99825786 %) | Approved | 27742486 |
| DrugRepV_2479 | Nizatidine | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) | Peptic ulcer disease | Active benign gastric ulcer | Active duodenal ulcer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.40022928 %) | Approved | 27742486 |
| DrugRepV_2487 | Esomeprazole Sodium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.29986636 %) | Approved | 27742486 |
| DrugRepV_2519 | Rosiglitazone Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.2146764 %) | Approved | 27742486 |
| DrugRepV_2558 | Ranitidine | Alimentary Tract and Metabolism | Duodenal ulcer | Pathological hypersecretion of gastric acid | Gastric ulcer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0007669 %) | Approved | 27742486 |
| DrugRepV_2577 | Cimetidine | Alimentary Tract and Metabolism | Peptic ulcers, heartburn and acid indigestion | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3280471 %) | Approved | 27742486 |
| DrugRepV_2590 | Sulfasalazine | Alimentary Tract and Metabolism | Inflammatory bowel diseases | Crohn disease | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4225909 %) | Approved | 27742486 |
| DrugRepV_2604 | Riboflavin | Alimentary Tract and Metabolism | Vitamin B2 deficiency | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6151556 %) | Approved, Investigational, Nutraceutical, Vet approved | 27742486 |
| DrugRepV_2635 | Rebamipide | Alimentary Tract and Metabolism | Stomach Ulcer | Keratoconjunctivitis Sicca | Gastric Adenoma | Early Gastric Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9454128 %) | Investigational | 27742486 |
| DrugRepV_2647 | Esomeprazole Magnesium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1210661 %) | Approved | 27742486 |
| DrugRepV_2648 | Pioglitazone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1624894 %) | Approved, Investigational | 27742486 |
| DrugRepV_2660 | Acarbose | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3477084 %) | Approved | 27742486 |
| DrugRepV_2661 | Biotin | Alimentary Tract and Metabolism | Nutritional supplementation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3585021 %) | Approved | 27742486 |
| DrugRepV_2664 | Miglitol | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.380669 %) | Approved | 27742486 |
| DrugRepV_2714 | Nicotinamide | Alimentary Tract and Metabolism | Dietary supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2083988 %) | Approved, Investigational | 27742486 |
| DrugRepV_2726 | Saxagliptin | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.414562 %) | Approved | 27742486 |
| DrugRepV_2754 | Mesalamine | Alimentary Tract and Metabolism | Ulcerative colitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.0005942 %) | Approved | 27742486 |
| DrugRepV_2761 | Glimepiride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1556333 %) | Approved | 27742486 |
| DrugRepV_2768 | Alfacalcidol | Alimentary Tract and Metabolism | Hyperparathyroidism, Hypocalcemia and Osteodystropy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.3172474 %) | Approved | 27742486 |
| DrugRepV_2788 | Tolbutamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.6951294 %) | Approved, Investigational | 27742486 |
| DrugRepV_2789 | Linagliptin | Alimentary Tract and Metabolism | Type 2 diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7159637 %) | Approved | 27742486 |
| DrugRepV_2797 | Ondansetron | Alimentary Tract and Metabolism | Nausea | Vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.9010506 %) | Approved | 27742486 |
| DrugRepV_2809 | Domperidone | Alimentary Tract and Metabolism | Dyspepsia, heartburn, epigastric pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.2614756 %) | Approved | 27742486 |
| DrugRepV_2819 | Vitamin C | Alimentary Tract and Metabolism | Vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.5679794 %) | Approved | 27742486 |
| DrugRepV_2848 | Glipizide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.5735462 %) | Approved, Investigational | 27742486 |
| DrugRepV_2850 | Palonosetron Hydrochloride | Alimentary Tract and Metabolism | Nausea and vomiting associated with cancer chemotherapy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.7579581 %) | Approved, Investigational | 27742486 |
| DrugRepV_2852 | Vildagliptin | Alimentary Tract and Metabolism | Hyperglycemia in type 2 diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8331475 %) | Approved | 27742486 |
| DrugRepV_2853 | Rimonabant | Alimentary Tract and Metabolism | Obesity | Type 2 diabetes or dyslipidaemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8569753 %) | Approved, Investigational | 27742486 |
| DrugRepV_2870 | Alverine Citrate | Alimentary Tract and Metabolism | Muscle spasms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.6069373 %) | Approved | 27742486 |
| DrugRepV_2910 | Orlistat | Alimentary Tract and Metabolism | Obesity | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.7414562 %) | Approved, Investigational | 27742486 |
| DrugRepV_2915 | Glyburide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.433422 %) | Approved | 27742486 |
| DrugRepV_3095 | Tetrahydrolipstatin | Alimentary Tract and Metabolism | Obesity | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.73 %) | Approved | 23275491 |
| DrugRepV_3158 | Glycyrrhizin | Alimentary Tract and Metabolism | Chronic hepatitis | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Experimental | 14670584 |
| DrugRepV_3166 | Glycyrrhizin | Alimentary Tract and Metabolism | Chronic hepatitis | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (5.2 Log) | Approved, Experimental | 14670584 |
| DrugRepV_3170 | Glycyrrhizin | Alimentary Tract and Metabolism | Chronic hepatitis | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (99 %) | Approved, Experimental | 14670584 |
| DrugRepV_3274 | Orlistat | Alimentary Tract and Metabolism | Obesity | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27177310 |
| DrugRepV_3585 | Bisacodyl | Alimentary Tract and Metabolism | Colon cleansing | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3586 | Bisacodyl | Alimentary Tract and Metabolism | Colon cleansing | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_4096 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Ebola virus | Bundibugyo | NA | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4097 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Marburg virus | Lake Victoria isolate | NA | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4098 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Influenza virus | A/turkey/ England/50-92/91 | | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4099 | Esomeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Ebola virus | Mayinga | NA | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4100 | Esomeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Ebola virus | Bundibugyo | NA | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4101 | Esomeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Marburg virus | Lake Victoria isolate | NA | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4102 | Esomeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Influenza virus | A/turkey/ England/50-92/91 | | Inhibition assay | Decrease (50 %) | Approved | 26069727 |
| DrugRepV_4576 | Glycyrrhizin | Alimentary Tract and Metabolism | Chronic hepatitis | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Experimental | 15715493 |
| DrugRepV_4653 | Palonosetron | Alimentary Tract and Metabolism | Nausea and vomiting associated with cancer chemotherapy | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27909576 |
| DrugRepV_5489 | Calcifediol | Alimentary Tract and Metabolism | Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, headache (continuing), increased thirst, increase in frequency of urination, irregular heartbeat, itching skin, loss of appetite, muscle pain, nausea or vomiting ( | Zika virus | PRVABC59 | NA | Cell viability assay | Decrease (50 %) | Approved, Nutraceutical | 31669333 |
| DrugRepV_5545 | Metformin | Alimentary Tract and Metabolism | Diabetes | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5549 | Migalastat | Alimentary Tract and Metabolism | Fabry disease | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5765 | Vitamin C | Alimentary Tract and Metabolism | Vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification | Dengue virus | NGC | | Plaque assay | No significant effect | Approved | 25313218 |
| DrugRepV_7611 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7612 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7627 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7628 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7681 | Domperidone | Alimentary Tract and Metabolism | Dyspepsia, heartburn, epigastric pain | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7687 | Metoclopramide | Alimentary Tract and Metabolism | Diabetic gastroparesis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7986 | Silymarin | Alimentary tract and metabolism | NA | Enterovirus | 41 | | Plaque assay | Decrease (50 %) | NA | 32293397 |
| DrugRepV_8136 | Nifuroxazide | Alimentary Tract And Metabolism | NA | Vaccinia virus | NA | | NA | Decrease (48.8 %) | Experimental | 32708182 |
| DrugRepV_8239 | Tolbutamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved, Investigational | 32708182 |
| DrugRepV_8311 | Esomeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Human immunodeficiency virus | NA | | Western blot | Decrease (50 %) | Approved | 32132561 |
| DrugRepV_8312 | Lansoprazole | Alimentary Tract and Metabolism | Gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease | Human immunodeficiency virus | NA | | Western blot | Decrease (50 %) | Approved, Investigational | 32132561 |
| DrugRepV_8313 | Pantoprazole | Alimentary Tract and Metabolism | Gastroesophageal reflux disease | Human immunodeficiency virus | NA | | Western blot | Decrease (50 %) | Approved | 32132561 |
| DrugRepV_8314 | Rabeprazole | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use | Human immunodeficiency virus | NA | | Western blot | Decrease (50 %) | Approved, Investigational | 32132561 |